Navigation Links
Unigene Provides 2012 Business Outlook
Date:1/9/2012

x countries.

Tarsa also currently has a Phase 2 osteoporosis prevention trial ongoing.  TAR01-201, is a Phase 2 double-blind study comparing oral recombinant salmon calcitonin to placebo in approximately 120 postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture. This proof-of-concept study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population.  Tarsa expects to report top-line results from this study in the second half of 2012.

Tarsa expects to file its New Drug Application (NDA) submission schedule to the FDA for OSTORA, in the second half of 2012.

Metabolic Peptide Programs Advancing in Preclinical Development

Unigene's lead proprietary anorexigenic peptide, UGP281, is currently in advanced preclinical development. An anorexigenic peptide is one that diminishes or controls appetite and offers potential therapeutic benefit to morbidly obese patients.

UGP281 is a peptide hormone analog that has shown an acute dramatic reduction in food intake in rat and dog model preclinical studies at low doses. The peptide has been produced by recombinant expression in E. coli and has also been formulated in enteric-coated capsules for oral delivery.

Longer term oral studies with UGP281 in dog models are currently ongoing. Unigene expects to file an Investigational New Drug (IND) application with the FDA and initiate Phase 1 clinical studies before the end of 2012.

On October 6, 2011, Unigene and Nordic Bioscience announced the companies established a Joint Development Vehicle (JDV) to progress up to three of Unigene's internally developed, proprietary calcitonin analogs through Phase 2 proof-of-concept in humans for the treatment of Type 2 diabetes, osteoarthritis and osteoporosis. Unigene and Nordic each own 50% of the JDV.

In exchange for 50% ownership interest in the JDV, Unigene has licensed, on an
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
2. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
3. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
4. Unigene Reports Third Quarter 2011 Financial Results
5. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
6. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
7. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
8. VIVUS Provides Qnexa Regulatory Update
9. New Product Planning Excellence Services Program Provides Road Map for Clinical Development Success in the Pharmaceutical Industry
10. ViroPharma Provides 2012 Outlook
11. Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Victoria Vein & Surgery Clinic is the only clinic ... in Victoria, Texas . The clinic specializes ... laser treatments for a variety of medical and cosmetic conditions. ... more services for their patients. Since adding laser tattoo removal, ... residents get rid of their unwanted ink. ...
(Date:3/27/2015)... , March 27, 2015   Cypher ... today announced new data showing that, compared to ... technology provided highly equivalent interpretations of whether ... and did so in a fraction of the ... way for more comprehensive genetic analysis in non-invasive ...
(Date:3/27/2015)... Inc. (NYSE and SIX: ZMH) is celebrating a key milestone in 2015 ... System. ,   ... the NexGen knee system, with its innovative design and component ... the NexGen knee have taken place worldwide. ... importance of design innovation and component quality for surgeons and patients alike," ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... commercial launch of MuGard, an FDA approved treatment for oral ... Access intends to commercially launch MuGard in North America ... pertaining to the launch include: , Manufacturing : ...
... Nov. 11 Pharma market research thought leaders are discovering ... opportunities in the pharmaceutical industry. The last twelve months ... Pharmaceutical market research is no exception. But those ... information today will certainly rise to be the new leaders ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 4Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 2
(Date:3/28/2015)... 2015 India Network visitor health ... available to all visitors who purchase the plan before ... are encouraged to purchase the insurance program as soon ... proper coverage for pre-existing medical conditions. Parents and grandparents ... medical conditions with serious consequences to their health. Many ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 One in ... according to research presented today at the American Orthopaedic ... The study examined the long term success of surgery ... “We examined survey data from 242 patients who underwent ... Justin P. Roe, MBBS, FRACS, from North Sydney Orthopaedic ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the ... the first time, key information for understanding and treating ... newly posted story on the Surviving Mesothelioma website. ... Columbia, the British Columbia Cancer Agency, and PhenoPath lab ... molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... 28, 2015 Healthpointe’s otolaryngologists, medical practitioners ... throat disorders, are now offering a wide variety ... which is characterized by the presence of phantom sounds ... people, tinnitus is a prevalent symptom that can arise ... is non-fatal, tinnitus can impede a person’s quality of ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 ... of dietary supplements announces the release of their ... was shown in two randomized, double-blind, placebo-controlled clinical ... and waist and hip size. MuffinStop™ is a ... indicus and Garcinia mangostana, fused together to create ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... reproductive success of both men and women is influenced by ... of Sheffield. The study, which was published yesterday (7 ... of Sciences , found that women with higher levels of ... to a larger number of children in societies with traditionally ...
... are immune to a stroke. You may feel healthy; you may ... more vulnerable than you know. That could be because of the ... a result of research from Hopital Notre Dame in Montreal, two ... so silent any more. Lead investigator, neurologist Dr. Alexandre ...
... Researchers from the BC Centre for Excellence in ... released a comprehensive study revealing that the 2008 IAS-USA ... benefits for individuals infected with HIV and society as ... in the research journal PLoS ONE , shows ...
... HACKENSACK, N.J. (June 07, 2010)The John Theurer Cancer Center ... Division of Radiation Oncology has recognized Joseph Hanley, Ph.D., ... his team for outstanding excellence in patient safety. ... exceptional work developing and maintaining Intensity-Modulated Radiation Therapy (IMRT) ...
... very different organisms, they share a surprising number of biological ... one of these mechanisms may be the answer for turning ... of the Molecular Biology and Ecology of Plants Department at ... on cell growth in plants. Now, in a laboratory setting, ...
... most immediate goal for caregivers is to get appropriate ... stop the seizing activity. In a paper published ... emergency medicine assistant professor Jason McMullan, MD, found that ... be with the least direct medication. In the ...
Cached Medicine News:Health News:Research shows personality can predict fertility 2Health News:Under 50? Silent duo could put you at risk for a big stroke 2Health News:Under 50? Silent duo could put you at risk for a big stroke 3Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 2Health News:Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs 3Health News:The John Theurer Cancer Center recognizes medical physics team for safety track record 2Health News:A turn-off for cancer 2Health News:Non-IV-administered medication just as effective in stopping seizures 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
... is a minimally invasive, highly effective surgical ... incontinence. GYNECARE TVT is positioned close to ... and when needed, TVT provides tension-free support ... The procedure takes approximately 20 to 30 ...
...
...
Medicine Products: